Request A Quote
Contact us to discuss how we can help you achieve your research goals
Clinical Panels

NovoFocus™ CR

NovoFocus CR offers comprehensive gene coverage for hereditary cancer screening by analysing whole exon regions of genes recommended by international guidelines in one sample and one test. This is particularly important for individuals who carry hereditary pathogenic variants and are at increased risk of developing cancer, as early detection allows for personalised screening programmes, preventive measures and proactive treatment to maximise health outcomes.

Advantages of NovoFocus CR with Novogene
Quality management

System that meets the requirements of national and international standards, including CAP accreditation

Flexible sequencing strategies

No limit on sample number

High capacity

Industry-leading turnaround time

High quality

Guaranteed Q30 ≥ 85%

Bioinformatics expertise

Publication-ready results and bioinformatic consultants available for data interpretation

NovoFocus CR Highlights
  • Comprehensive genomic profiling of 106 genes associated with inherited cancers
  • Beneficial for those with a positive family history of inherited cancers over several generations
  • CAP-compliant sequencing laboratory
  • High read depth increases the accuracy of analysis
  • A smaller data set for faster and easier analysis compared to whole genome sequencing

Sample Requirements

Sample type Amount Volume Concentration Description Collection tube recommended
Genomic DNA
 ≥ 1 µg — — No degradation or slight degradation
1.5 ml or 2 ml microcentrifuge tube
FFPE* genomic DNA ≥ 1 µg ≥ 20 µl ≥ 10 ng/µl Fragments should be longer than 1500 bp
FFPE* tissue
 ≥ 10 sections of 5-10 µm thickness
Tissue area > 25 mm2		 — — Operation tissue paraffin slides
Pathological tissue patch box / 2 ml microcentrifuge tube
≥ 20 patches (> 3 mm2 per patch)
≥ 30 patches (> 2 mm2 per patch)		 — Biopsy tissue paraffin slides

NovoFocus™ CR Workflow

What Does NovoFocus™ CR Detect?

NovoFocus™ CR contains 106 genes associated with hereditary cancers. The genes are carefully selected with the potential risks of developing one or more of the following hereditary tumors.

Associated Genes Across 8 Important Hereditary Cancer Types
Genes Breast Ovarian Colorectal Uterine Renal Pancreatic Gastric Prostate Others
APC ● ● ●
ATM ● ● ● ● ● ●
AXIN2 ●
BARD1 ●
BRCA1 ● ● ● ● ● ●
BRCA2 ● ● ● ● ● ●
BRIP1 ● ●
BUB1 ●
BUB1B ● ●
BUB3 ●
CDH1 ● ● ●
CDKN2A ● ●
CHEK2 ● ● ● ● ●
ELAC ●
EPCAM ● ● ● ● ● ● ●
FH ●
FLCN ● ●
HNF1A ●
HOXB13 ●
MET ●
MLH1 ● ● ● ● ● ● ● ●
MLH3 ● ● ●
MSH2 ● ● ● ● ● ● ●
MSH6 ● ● ● ● ● ●
MUTYH ●
NBN ● ● ●
PALB2 ● ● ● ●
PMS1 ●
PMS2 ● ● ● ● ● ● ●
PRSS1 ●
PTEN ● ● ● ● ●
RAD51C ● ● ●
RAD51D ● ● ●
RNASEL ●
SDHA/SDHB
●
●
SDHC/SDHD
SMAD4 ● ●
STK11 ● ● ● ● ● ● ●
TP53 ● ● ● ● ●
VHL ● ● ●
Download Demo Report of NovoFocus™ Cancer Risk (CR)

Data Interpretations

(*OMIM Database and NCCN Guidelines)

Positive Results Uncertain Variants Negative Results
Pathogenic/Likely pathogenic Medical Management Based on Recommendations for the Specific Variants Uncertain Significance Variant Surveillance and Medical Management Based on Personal/Family Cancer History Likely benign/Benign Recommendations based on general population cancer risk screening

More Services

Clinical TruSeq Exome RNA Sequencing

NovoPM 2.0

Patient’s Case Study

NovoFocus™ CR

NovoPM 2.0

Cancer Immunotherapy Biomarkers

We use cookies to enhance your browsing experience. To learn more please see our Privacy Policy

By continuing you agree to our use of cookies.

CONTINUE